Pharvaris N.V. Files 6-K with Q2 2024 Financial Updates

Ticker: PHVS · Form: 6-K · Filed: 2024-08-14T00:00:00.000Z

Sentiment: neutral

Topics: financial-update, 6-K, pharmaceutical

TL;DR

Pharvaris 6-K shows Q2 2024 financials, including reserves and expenses. Check for cash burn and IP costs.

AI Summary

Pharvaris N.V. filed a 6-K report on August 14, 2024, detailing financial information as of June 30, 2024. The filing includes data related to various financial reserves and liabilities, such as 'Other Reserves' and 'Reserve of Exchange Differences on Translation' as of December 31, 2023, and 'Nonclinical Accrued Liabilities' as of June 30, 2024. It also references personnel expenses and intellectual property costs for periods in 2023 and 2024.

Why It Matters

This filing provides a snapshot of Pharvaris N.V.'s financial position and operational costs, offering insights into the company's resource allocation and financial health for investors and analysts.

Risk Assessment

Risk Level: low — This filing is a routine 6-K report providing financial updates and does not indicate any immediate or significant new risks.

Key Numbers

Q2 2024 — Reporting Period (The financial data pertains to the second quarter of 2024.)
2023-12-31 — Previous Year End (Financial reserves are reported as of this date.)
2024-06-30 — Current Period End (Key liabilities and financial data are reported as of this date.)

Key Players & Entities

Pharvaris N.V. (company) — Filer of the report
20240630 (date) — Reporting period end date
20240814 (date) — Filing date
0000950170-24-096640 (other) — Accession number for the filing
Leerink Partners (company) — Mentioned in relation to a member

FAQ

What specific financial reserves are detailed in the filing as of December 31, 2023?

The filing details 'Other Reserves' and 'Reserve of Exchange Differences on Translation' as of December 31, 2023.

What is the reporting period for the financial data presented in this 6-K?

The conformed period of report is June 30, 2024 (Q2 2024).

When was this 6-K filing submitted to the SEC?

This filing was submitted on August 14, 2024.

Are there any specific expense categories mentioned for 2023 and 2024?

Yes, the filing mentions 'Personnel Expenses' and 'Intellectual Property Costs' for periods in 2023 and 2024.

What type of company is Pharvaris N.V. classified as by the SEC?

Pharvaris N.V. is classified under 'Pharmaceutical Preparations' (SIC code 2834).

From the Filing

0000950170-24-096640.txt : 20240814 0000950170-24-096640.hdr.sgml : 20240814 20240814065114 ACCESSION NUMBER: 0000950170-24-096640 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 90 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240814 DATE AS OF CHANGE: 20240814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharvaris N.V. CENTRAL INDEX KEY: 0001830487 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40010 FILM NUMBER: 241204051 BUSINESS ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 BUSINESS PHONE: 31 (0)71 203 6410 MAIL ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Pharvaris, B.V. DATE OF NAME CHANGE: 20201029 6-K 1 phvs-20240630.htm 6-K 6-K 0001830487 false 2024 --12-31 Q2 2024-06-30 0001830487 phvs:PharvarisGmbhMember 2024-01-01 2024-06-30 0001830487 phvs:LeerinkPartnersMember 2024-04-01 2024-04-30 0001830487 ifrs-full:OtherReservesMember 2023-12-31 0001830487 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-12-31 0001830487 phvs:PharvarisIncMember 2023-01-01 2023-06-30 0001830487 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember phvs:BlackScholesFormulaMember 2024-04-11 2024-04-11 0001830487 phvs:OtherAccruedLiabilitiesMember 2023-12-31 0001830487 phvs:IntellectualPropertyCostsMember 2023-04-01 2023-06-30 0001830487 2023-04-01 2023-06-30 0001830487 phvs:PersonnelExpensesMember 2023-01-01 2023-06-30 0001830487 phvs:PharvarisIncMember 2024-01-01 2024-06-30 0001830487 phvs:NonclinicalAccruedLiabilitiesMember 2024-06-30 0001830487 phvs:StockOptionsMember 2024-06-30 0001830487 ifrs-full:IssuedCapitalMember 2023-06-30 0001830487 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2023-04-01 2023-06-30 0001830487 phvs:LeerinkPartnersMember 2024-01-01 2024-06-30 0001830487 phvs:ClinicalExpensesMember 2023-01-01 2023-06-30 0001830487 2024-01-01 2024-06-30 0001830487 ifrs-full:RetainedEarningsMember 2024-06-30 0001830487 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-12-31 0001830487 phvs:ManufacturingAccruedLiabilitiesMember 2024-06-30 0001830487 phvs:ManufacturingCostsMember 2023-04-01 2023-06-30 0001830487 2023-06-30 0001830487 phvs:PharvarisNetherlandsBvMember 2023-01-01 2023-06-30 0001830487 2024-04-11 2024-04-11 0001830487 ifrs-full:SharePremiumMember 2024-01-01 2024-06-30 0001830487 ifrs-full:RetainedEarningsMember 2023-06-30 0001830487 phvs:RestrictedStockUnitsMember phvs:EmployeesMember 2024-01-01 2024-06-30 0001830487 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember phvs:BlackScholesFormulaMember 2024-04-15 2024-04-15 0001830487 2024-01-02 2024-01-02 0001830487 phvs:OtherAccruedLiabilitiesMember 2024-06-30 0001830487 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2023-01-01 2023-06-30 0001830487 phvs:RestrictedStockUnitsMember 2023-12-31 0001830487 phvs:ClinicalExpensesMember 2023-04-01 2023-06-30 0001830487 phvs:ManufacturingAccruedLiabilitiesMember 2023-12-31 0001830487 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2024-06-30 0001830487 ifrs-full:RetainedEarningsMember 2023-12-31 0001830487 ifrs-full:OtherReservesMember 2023-06-30 0001830487 ifrs-full:RetainedEarningsMember 2023-01-01 2023-06-30 0001830487 ifrs-full:SharePremiumMember 2023-06-30 0001830487 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2024-01-01 2024-06-30 0001830487 ifrs-full:IssuedCapitalMember 2023-12-31 0001830487 phvs:PersonnelRelatedAccrualsMember 2023-12-31 0001830487 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2023-12-31 0001830487 phvs:StockOptionsGrantedToBoardOfDirectorsMember phvs:BlackScholesFormulaMember 2024-04-11 0001830487 2023-01-01 2023-06-30 0001830487 phvs:RestrictedStockUnitsMember 2024-06-30 0001830487 phvs:Int